TY - JOUR
T1 - Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults
AU - Silverberg, Jonathan I.
AU - Gelfand, Joel M.
AU - Margolis, David J.
AU - Boguniewicz, Mark
AU - Fonacier, Luz
AU - Grayson, Mitchell H.
AU - Ong, Peck Y.
AU - Chiesa Fuxench, Zelma C.
AU - Simpson, Eric L.
N1 - Funding Information:
Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association (NEA) and sponsored by Sanofi Genzyme and Regeneron.
Publisher Copyright:
© 2019 The Authors
PY - 2019/10
Y1 - 2019/10
N2 - Quality-of-life assessments are not standardized in atopic dermatitis (AD). We sought to determine the validity of the Short Form (SF)-12, a generic quality-of-life assessment, in AD and compare its measurement properties with the Dermatology Life Quality Index (DLQI). A cross-sectional, population-based study of 3,495 adults was performed, including 602 adults who met the modified United Kingdom Working Party Criteria for AD. The SF-12 mental component score and the SF-Six Dimension (SF-6D) had a strong correlation with each other and moderate inverse correlations with the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring Atopic Dermatitis, the Patient-Oriented Scoring Atopic Dermatitis–itch, the Patient-Oriented Scoring Atopic Dermatitis–sleep, and the Numerical Rating Scale of pain (Pearson correlations, P < 0.0001 for all). The SF-12 mental component score and the SF-6D showed good discriminant validity as judged by the analysis of variance and receiver operating curves. The SF-12 physical component score had weak correlations with AD severity assessments and poor discriminant validity. The DLQI had better convergent and discriminant validity than the SF-12. The SF-12 and the DLQI showed good internal consistency (Cronbach alpha, 0.89 and 0.94, respectively). Differential item functioning was found for items in the SF-12 and the DLQI. Floor effects were observed for the DLQI but not for the SF-12 mental component score, the SF-12 physical component score, and the SF-6D. Severity thresholds were selected. In conclusion, the SF-12 mental component score and the SF-6D showed good validity in AD but inferior construct validity compared with the DLQI.
AB - Quality-of-life assessments are not standardized in atopic dermatitis (AD). We sought to determine the validity of the Short Form (SF)-12, a generic quality-of-life assessment, in AD and compare its measurement properties with the Dermatology Life Quality Index (DLQI). A cross-sectional, population-based study of 3,495 adults was performed, including 602 adults who met the modified United Kingdom Working Party Criteria for AD. The SF-12 mental component score and the SF-Six Dimension (SF-6D) had a strong correlation with each other and moderate inverse correlations with the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring Atopic Dermatitis, the Patient-Oriented Scoring Atopic Dermatitis–itch, the Patient-Oriented Scoring Atopic Dermatitis–sleep, and the Numerical Rating Scale of pain (Pearson correlations, P < 0.0001 for all). The SF-12 mental component score and the SF-6D showed good discriminant validity as judged by the analysis of variance and receiver operating curves. The SF-12 physical component score had weak correlations with AD severity assessments and poor discriminant validity. The DLQI had better convergent and discriminant validity than the SF-12. The SF-12 and the DLQI showed good internal consistency (Cronbach alpha, 0.89 and 0.94, respectively). Differential item functioning was found for items in the SF-12 and the DLQI. Floor effects were observed for the DLQI but not for the SF-12 mental component score, the SF-12 physical component score, and the SF-6D. Severity thresholds were selected. In conclusion, the SF-12 mental component score and the SF-6D showed good validity in AD but inferior construct validity compared with the DLQI.
UR - http://www.scopus.com/inward/record.url?scp=85067885495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067885495&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2019.03.1152
DO - 10.1016/j.jid.2019.03.1152
M3 - Article
C2 - 31009616
AN - SCOPUS:85067885495
SN - 0022-202X
VL - 139
SP - 2090-2097.e3
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 10
ER -